Shares of None company Ionis Pharmaceuticals climbed 4.4% this evening. Here are some quick facts to get you started if you are interested in the stock:
-
Ionis Pharmaceuticals has logged a 28.0% 52 week change, compared to 14.0% for the S&P 500
-
IONS has an average analyst rating of buy and is -3.12% away from its mean target price of $53.29 per share
-
Its trailing earnings per share (EPS) is $-2.87, which brings its trailing Price to Earnings (P/E) ratio to -18.0. The Health Care sector's average P/E ratio is None
-
The company's forward earnings per share (EPS) is $-3.69 and its forward P/E ratio is -14.0
-
The company has a Price to Book (P/B) ratio of 23.47 in contrast to the Health Care sector's average P/B ratio is None
-
The company's free cash flow for the last fiscal year was $-569336000 and the average free cash flow growth rate is -16.9%
-
Ionis Pharmaceuticals's revenues have an average growth rate of 0.4% with operating expenses growing at None%. The company's current operating margins stand at -61.1%